Compound description
What is MK-677 powder (Ibutamoren)
MK-677 (ibutamoren) is a non-peptide agonist of the ghrelin receptor GHSR-1a and a growth hormone secretagogue. Structurally it belongs to the spiroindoline class: a scaffold engineered to fit a receptor that nature built for a peptide ligand (Wikipedia).
The main advantage is oral activity. Every peptide secretagogue, from ipamorelin to GHRP-6, requires injection and acts briefly. MK-677 is taken by mouth and produces sustained elevation of growth hormone and IGF-1 levels (Svensson et al., J Clin Endocrinol Metab 1998). It is a fundamentally different instrument for the same GH/IGF-1 endpoints.
Mechanism. Ghrelin is produced mainly in the stomach and acts through GHSR-1a, a G protein-coupled receptor expressed in the hypothalamus, pituitary and peripheral tissues. MK-677 mimics that action: the activated receptor triggers pulsatile growth hormone release from the pituitary, with IGF-1 rising downstream (Wikipedia). Crucially, this amplifies the body's own secretion rather than administering hormone from outside — the physiological pulsatile pattern of release is preserved.
Cortisol is unchanged. This is a key point of selectivity: the compound produces sustained increases in plasma growth hormone and IGF-1 without affecting cortisol levels (Copinschi et al., Neuroendocrinology 1997). Earlier secretagogues could not claim this, and incidental cortisol elevation is precisely what closed several programmes in the class.
Duration of action and absence of tolerance. The elimination half-life in dogs is 4–6 hours, yet after a single oral dose IGF-1 in humans remains elevated for up to 24 hours (Wikipedia) — hence once-daily dosing. Equally important, the effect on growth hormone secretion persists on prolonged administration without tachyphylaxis: the system does not habituate and stop responding.
Sleep. One of the most reproducible findings for this compound is its effect on sleep architecture. Work by Copinschi et al. showed that MK-677 extends slow-wave sleep — the deepest, most restorative stage (Copinschi et al., Neuroendocrinology 1997). This fits the physiology: the main natural peak of growth hormone secretion occurs precisely during deep sleep.
Protection against catabolism. A separate line of work concerns the ability to maintain nitrogen balance under caloric deficit. This follows logically from the mechanism: the GH/IGF-1 axis shifts metabolism toward preserving lean mass, which is why the compound has been studied in wasting and age-related sarcopenia models (Svensson et al., J Clin Endocrinol Metab 1998).
It is not a SARM. The compound is often sold alongside selective androgen receptor modulators, but mechanistically that label is wrong: ibutamoren has no androgenic activity, does not bind the androgen receptor and does not suppress endogenous testosterone. It is a growth hormone secretagogue and sits beside SARMs only by catalogue convention.
Body composition in older adults. A randomised study in healthy older adults evaluated an oral ghrelin mimetic for its effects on body composition and clinical outcomes (Ann Intern Med, 2008). It is one of the few studies in this class carried out in humans rather than models.
Bone. In postmenopausal women with osteoporosis, MK-677 was studied both alone and combined with alendronate for markers of bone turnover and bone mineral density (J Clin Endocrinol Metab, 2001). The rationale is direct: the GH/IGF-1 axis participates in bone remodelling.
Haemodialysis. In a randomised blinded study, an oral ghrelin receptor agonist raised serum IGF-1 in haemodialysis patients (Nephrol Dial Transplant, 2018) — a population in whom catabolism and muscle loss are the central clinical problem.
Why the effects are so broad. GHSR is not confined to the pituitary: the receptor is present in brain regions governing appetite, mood, biological rhythms, memory and cognition. This is why ghrelin receptor agonists influence several physiological systems at once rather than growth hormone secretion alone.
Supplied as a powder, purity ≥98%, CAS 159634-47-6.
